Xarelto (rivaroxaban) / J&J 
Welcome,         Profile    Billing    Logout  
 97 Diseases   247 Trials   247 Trials   14602 News 


«12...142143144145146147148149150151152...170171»
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Eliquis (apixaban) / BMS
    Clinical, Journal:  Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions. (Pubmed Central) -  Aug 1, 2019   
    Drugs that modify p-glycoprotein may interact with all direct oral anticoagulants, and modifiers of cytochrome 3A4 may interact with rivaroxaban and apixaban...New data on anticoagulant drug interactions is available almost daily, so it is vital that clinicians regularly search interaction databases and the literature for updated management strategies. Skilled drug interaction management will improve outcomes and prevent adverse events in patients taking oral anticoagulants.
  • ||||||||||  warfarin / Generic mfg.
    Trial completion date, Trial primary completion date:  CANVAS: Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer (clinicaltrials.gov) -  Jul 29, 2019   
    P=N/A,  N=940, Recruiting, 
    The choice of anticoagulation should be individualized based on the risk factor profile of the patient. Trial completion date: Sep 2019 --> Aug 2020 | Trial primary completion date: Sep 2019 --> Jun 2020
  • ||||||||||  Clinical, Review, Journal:  Anticoagulation in geriatric patients with atrial fibrillation : With what and for whom no more? (Pubmed Central) -  Jul 28, 2019   
    A regular monitoring of the indications for NOACs is indispensable (as for all other medications). Especially elderly patients have the greatest benefit from NOAC along with a low renal elimination rate and they should certainly not be withheld from elderly patients who have a clear need for oral anticoagulation.
  • ||||||||||  rivaroxaban / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date, Head-to-Head:  RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial (clinicaltrials.gov) -  Jul 28, 2019   
    P2,  N=1005, Active, not recruiting, 
    Especially elderly patients have the greatest benefit from NOAC along with a low renal elimination rate and they should certainly not be withheld from elderly patients who have a clear need for oral anticoagulation. Recruiting --> Active, not recruiting | Trial completion date: Aug 2018 --> Dec 2019 | Trial primary completion date: Aug 2018 --> Dec 2019
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Cardilor (amiodarone) / Generic Mfg.
    Journal:  Rivaroxaban With and Without Amiodarone in Renal Impairment. (Pubmed Central) -  Jul 26, 2019   
    Ongoing studies and scientific questions that are important to define the future for catheter-based LAA closure are discussed in this review. No abstract available
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J
    Journal:  Rivaroxaban for prevention and treatment of venous thromboembolism. (Pubmed Central) -  Jul 26, 2019   
    Rivaroxaban, an oral factor Xa inhibitor, was the first direct oral anticoagulant licensed for VTE prevention and treatment. This paper provides the rationale for factor Xa as a target for anticoagulants, describes the development of rivaroxaban, reviews its pharmacological profile, discusses the clinical trials with rivaroxaban for VTE prevention and treatment and highlights areas of uncertainty.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Eliquis (apixaban) / BMS
    Clinical, Journal:  Managing Direct Oral Anticoagulants in Patients With Antiepileptic Medication. (Pubmed Central) -  Jul 24, 2019   
    This case illustrates and supports the concerns regarding concomitant use of these medications. Additionally, in this case the interaction was managed with concentration-guided dosing of apixaban, suggesting this approach may represent a feasible strategy for managing patients requiring treatment with direct-acting oral anticoagulants and enzyme-inducing antiepileptic drugs.
  • ||||||||||  rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
    Clinical, Journal:  Assessment of direct oral anticoagulant assay use in clinical practice. (Pubmed Central) -  Jul 24, 2019   
    Clinical decisions following level results depended on indication for ordering and were most commonly used to determine whether or not to proceed with an invasive procedure. The results of our study suggest while DOAC assays are generally ordered for useful indications, there is still a lack of understanding of when levels should be drawn and how to interpret DOAC assay results.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Eliquis (apixaban) / BMS
    Clinical, Retrospective data, Journal:  Shorter hospital stays in epistaxis patients with atrial fibrillation when taking rivaroxaban or apixaban versus phenprocoumon. (Pubmed Central) -  Jul 24, 2019   
    A correlation between CHADS-VASc score (risk score for apoplexy in patients with AF, p = 0.01), HAS-BLED score (score for assessment of major bleeding in patients taking anticoagulants with AF, p = 0.006), and length of hospital stay (p = 0.002) with recurrence of epistaxis was found. Shorter hospital stays and exclusively anterior bleeding was noted in AF patients taking rivaroxaban and apixaban, whereas AF patients taking phenprocoumon stayed in hospital longer and had more posterior bleeding.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J
    Journal:  Prevention of livedoid vasculopathy recurrence by prolonged administration of rivaroxaban. (Pubmed Central) -  Jul 21, 2019   
    He was formerly treated with prostacyclin infusions, acetylsalicylic acid, intravenous immunoglobulins, different systemic antibiotics and a skin grafting. At admission an antithrombotic therapy with enoxaparin (Clexane(®) ) in a dose of 1 mg/ kg bodyweight (100 mg) once daily was initiated.
  • ||||||||||  rivaroxaban / Generic mfg.
    Clinical, Review, Journal:  Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations. (Pubmed Central) -  Jul 20, 2019   
    This approach has been tested in both acute and stable settings of patients with cardiovascular disease manifestations. The present manuscript provides an overview on the rationale and clinical trial updates on the role of oral anticoagulant therapy, in particular rivaroxaban used at the so-called vascular protection dose, in adjunct to antiplatelet therapy (i.e. aspirin), a strategy known as dual pathway inhibition, for secondary prevention of ischemic recurrences in patients with stable atherosclerotic disease manifestations.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Eliquis (apixaban) / BMS
    Retrospective data, Journal:  Comparison of efficiency and safety of rivaroxaban, apixaban and enoxaparin for thromboprophylaxis after arthroplastic surgery: A meta-analysis. (Pubmed Central) -  Jul 19, 2019   
    In analysis of safety outcomes, bleeding events occurred in 3.41% patients of rivaroxaban group compared with 2.84% patients of the control groups; bleeding events in apixaban groups were 4.09% compared with the control groups 4.64%. Bleeding events occurred in 3.51% patients of enoxaparin group, slightly lower than 5.82% of the control group.  Direct oral anticoagulant, rivaroxaban might have better efficacy outcomes in thromboprophylaxis after arthroplastic surgery; however apixaban showed no significantly different efficacy outcomes compared with enoxaparin, and enoxaparin may have equal or even better safety outcomes compared with direct oral anticoagulants.